Devonian Health Group Inc.
OTC: DVHGF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Andre Boulet
- Employees
- 6
- Headquarters
- Québec, Canada
- IPO year
- 2022
- Market cap
- $19.5M
- Website
- https://groupedevonian.com
Loading DVHGF…
Loading profile data…Frequently asked questions about DVHGF
What does Devonian Health Group Inc. (DVHGF) do?
Devonian Health Group Inc. specializes in the creation of botanical-based pharmaceutical drugs. Its leading product candidate, Thykamine, is currently undergoing Phase IIa clinical trials to treat conditions such as ulcerative colitis and atopic dermatitis. The company's development pipeline also includes Pantoprazole Magnesium for addressing ga...
Where does DVHGF trade?
Devonian Health Group Inc. (DVHGF) trades on the Other OTC.
What sector is DVHGF in?
Devonian Health Group Inc. (DVHGF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Devonian Health Group Inc.?
Andre Boulet is the chief executive officer of Devonian Health Group Inc. (DVHGF).
Where is Devonian Health Group Inc. headquartered?
Devonian Health Group Inc. is headquartered in Canada.
Does DVHGF pay a dividend?
Devonian Health Group Inc. (DVHGF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did DVHGF go public?
Devonian Health Group Inc. (DVHGF) completed its initial public offering in 2022.